法洛四联症外科修复术后结局:系统评价与荟萃分析
该系统评价与荟萃分析检索2000年1月至2018年7月文献,纳入143篇论文、137个队列、21,427例患者,总随访147,430患者年。TOF可在低龄期手术修复,围术期及远期死亡率低,但再干预率较高,需终身密切随访。
要点
- TOF可在低龄期完成根治,围术期与远期死亡率均较低
- 术后再干预负担突出,需终身密切随访
- 跨环补片与跨心室切口在纳入队列中应用比例较高
核心结论
- 法洛四联症可在低龄期行外科根治,围术期及远期死亡率低,但再干预率较高,临床过程需终身密切随访。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、PubMed、Embase、Web of Science、Cochrane及Google Scholar 2000年1月至2018年7月文献。
- 共纳入143篇论文、137个独立队列、21,427例患者,总随访147,430患者年。
- 采用对数转换后随机效应模型合并估计死亡与再干预率,并通过亚组分析和荟萃回归评估异质性。
主要发现
- 总体平均根治年龄3.7±5.6岁;排除仅针对成人根治的论文后平均年龄0.5±2.5岁。
- 既往姑息分流(107项研究)、经心室切口(81项研究)、跨环补片(124项研究)使用比例分别为16%(范围0%-78%)、39%(范围0%-100%)、49%(范围0%-100%)。
- 使用跨环补片者中单瓣重建占15%(范围0%-100%,49项研究)。
- 最常见遗传异常为唐氏综合征,合并患病率4.6%(范围0%-12.3%)。
关键数值与推荐
- 早期死亡合并估计为2.84%(95%CI 2.34-3.45)。
- 远期死亡合并估计为0.42%/年(95%CI 0.33-0.54)。
- 远期心脏死亡合并估计为0.26%/年(95%CI 0.21-0.34)。
- 瓣膜相关死亡0.20%/年(95%CI 0.15-0.26),非瓣膜相关死亡0.17%/年(95%CI 0.12-0.22)。
- 再干预合并估计为2.26%/年(95%CI 1.86-2.75)。
临床怎么用
- 可将低围术期及远期死亡风险作为TOF根治术后的预期结局向患者家属说明。
- 鉴于再干预率达2.26%/年,应规划终身密切随访与再干预评估。
- 对使用跨环补片等术式的患者,随访中需重点关注再干预风险。
局限性
- 纳入研究间存在异质性,部分指标范围跨度大(如跨环补片使用0%-100%)。
- 合并估计基于观察性文献的随机效应模型,未报告各研究偏倚风险细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart disease. Intracardiac correction was pioneered by Walton Lillehei in 1955 and has since then gone through major developments. The aim of this study was to provide a systematic literature review of published results on the long-term outcome of complete surgical correction of TOF. METHODS: MEDLINE, PubMed, Embase, Web of Science, Cochrane, and Google Scholar were systematically searched for literature published between January 2000 and July 2018. Pooled estimates with a random effects model after log-transformation were calculated for mortality and reintervention. Potential heterogeneity was assessed by subgroup analyses and meta-regression. RESULTS: A total of 143 papers of 137 distinct cohorts comprising 21,427 patients and total follow-up duration of 147,430 patient-years were included. Overall mean age at correction was 3.7 ± 5.6 years, but excluding papers exclusively focusing on correction in adults yielded a mean age of 0.5 ± 2.5 years at correction. Previous palliative shunts (107 studies), a transventricular approach (81 studies), and a transannular patch (124 studies) were used in 16% (range 0%-78%), 39% (range 0%-100%), and 49% (range 0%-100%) of the patients. respectively. In case a transannular patch was used, monocusp reconstruction was applied in 15% (range 0%-100%) (49 studies). The most common genetic abnormality was Down syndrome, with a pooled estimated prevalence of 4.6% (range 0%-12.3%). The pooled estimates of early and late mortality were 2.84% (95% confidence interval [CI], 2.34-3.45) and 0.42%/year (95% CI, 0.33-0.54), respectively. The pooled estimate of late cardiac mortality was 0.26%/year (95% CI, 0.21-0.34). Valve-related mortality and non-valve-related mortality had pooled estimates of 0.20%/year (95% CI, 0.15-0.26) and 0.17%/year (95% CI, 0.12-0.22), respectively. The pooled estimate of reintervention was 2.26%/year (95% CI, 1.86-2.75). CONCLUSIONS: TOF can be surgically corrected at a young age with low perioperative and long-term mortality. Life-long intensive follow-up and substantial reintervention rates characterize the clinical course.
引用
- Romeo JLR, Etnel JRG, Takkenberg JJM, et al. Outcome after surgical repair of tetralogy of Fallot: A systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2019. PMID: 37452468. doi:10.1016/j.jtcvs.2019.08.127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。